Literature DB >> 8827195

Treatment algorithms in treatment-resistant depression.

J D Amsterdam1, M Hornig-Rohan.   

Abstract

When faced with a patient having treatment-resistant depression, it is essential to maintain a systematic approach to diagnosis and treatment: 1. Consider the presence of comorbid medical or psychiatric illness that may contribute to or cause the refractory state 2. Determine the affective subtype of depression (e.g., unipolar vs. phenotypic variant of bipolar depression) 3. Ensure the presence of adequate antidepressant dosage, plasma concentrations (where applicable), and duration of treatment 4. Apply systematic treatment algorithms, which means (1) initiate the most efficacious "first-line" therapy for a specific depressive subtype (even if that is an MAOI) and (2) initiate augmentation strategies in a systematic fashion. Augmentation strategies should be initiated only after first reviewing prior therapy, considering available treatment alternatives, and examining the relative risk:benefit ratio for each treatment option in the current clinical context. Following these guidelines should prevent the development of "therapeutic nihilism" in both the patient and physician, as well as enhance the ultimate treatment outcome for patients with treatment-resistant depression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827195     DOI: 10.1016/s0193-953x(05)70293-8

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  19 in total

1.  Pharmacologic management of refractory depression.

Authors:  S Chehil; S Devarajan; S M Dursun
Journal:  Can Fam Physician       Date:  2001-01       Impact factor: 3.275

2.  Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?

Authors:  Carole Lavigne; Jocelyn Yelle; Gilles Sauve; Alain R Thierry
Journal:  AAPS PharmSci       Date:  2002

Review 3.  [Therapy resistance to antidepressants. Definition, prevalence, predictors, and interventional possibilities].

Authors:  H-J Möller
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

4.  The role of monoamine oxidase inhibitors in current psychiatric practice.

Authors:  Jess G Fiedorowicz; Karen L Swartz
Journal:  J Psychiatr Pract       Date:  2004-07       Impact factor: 1.325

5.  The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder.

Authors:  Lois Jessen; Lawrence J Kovalick; Albert J Azzaro
Journal:  P T       Date:  2008-04

Review 6.  A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents.

Authors:  J Renaud; D Axelson; B Birmaher
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

7.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

Review 8.  Use of antidepressants in older patients with co-morbid medical conditions: guidance from studies of depression in somatic illness.

Authors:  Gary J Kennedy; Paula Marcus
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 9.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

10.  Olanzapine and fluoxetine combination in severe or resistant depression.

Authors:  R M Haridas; S R Parkar; Ram Ghulam; Gautam Amin; K G Thombre; A Srivastava; N Bhuvaneshwari; S Telang; Monika Obrah; Nandkishore Toraskar; R K Jalali; Kiran V Marthak
Journal:  Indian J Psychiatry       Date:  2003-10       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.